Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Present with GPP or EP based on an investigator-confirmed diagnosis and meet the associated criteria~  * GPP: Meet the criteria for GPP set by Ministry of Health, Labour and Welfare (MHLW) at screening and baseline regardless of IL-36 mutation status.~ * EP: Diagnosed to have BSA ≥80% involvement (with inflammatory erythema) at screening and baseline.~* Candidates for phototherapy and/or systemic therapy~* Men must agree to use a reliable method of birth control during the study~* Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~Exclusion Criteria:~* History of drug-induced psoriasis~* Concurrent or recent use of any biologic agent~* Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study~* Have previously received ixekizumab~* Serious disorder or illness other than psoriasis~* Serious infection within the last 12 weeks~* Breastfeeding or nursing (lactating) women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab (Type: EXPERIMENTAL): Induction Dosing Period:~Participants received 160 milligrams (mg) ixekizumab subcutaneously (SC) as 2 injections at Week 0 followed by 80 mg ixekizumab SC as 1 injection at Week 2, 4, 6, 8 and 10.~Maintenance Dosing Period:~Participants with Global Improvement Score (GIS) = 1 at Week 12 are responders who will complete the study.~Participants who are inadequate responders (GIS ≥2 at Week 12 and based on the investigators' discretion) will be administered 80 mg ixekizumab SC as 1 injection at Week 12, 14, 16, and 18 or until they achieve a GIS score of 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).